Drug Profile
Navicixizumab - Mereo BioPharma/Feng Biosciences
Alternative Names: anti-DLL4/VEGF bispecific antibody - Mereo BioPharma/Feng Biosciences; OMP 305B83Latest Information Update: 02 Apr 2024
Price :
$50
*
At a glance
- Originator OncoMed Pharmaceuticals
- Developer Feng Biosciences; OncoMed Pharmaceuticals
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action DLL4 protein inhibitors; Stem cell modulators; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Breast cancer; Colorectal cancer; Fallopian tube cancer; Gastric cancer; Ovarian cancer; Peritoneal cancer
- No development reported Solid tumours
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for phase-I development in Fallopian-tube-cancer(Combination therapy, Second-line therapy or greater) in USA (IV, Infusion)
- 28 Jan 2023 No recent reports of development identified for phase-I development in Ovarian-cancer(Combination therapy, Second-line therapy or greater) in USA (IV, Infusion)
- 28 Jan 2023 No recent reports of development identified for phase-I development in Peritoneal-cancer(Combination therapy, Second-line therapy or greater) in USA (IV, Infusion)